CSIMarket
 
Arrowhead Pharmaceuticals Inc   (ARWR)
Other Ticker:  
 
 
Price: $28.1400 $-0.14 -0.495%
Day's High: $28.36 Week Perf: -1.44 %
Day's Low: $ 27.21 30 Day Perf: -4.84 %
Volume (M): 1,274 52 Wk High: $ 42.48
Volume (M$): $ 35,845 52 Wk Avg: $30.73
Open: $28.28 52 Wk Low: $20.67



 Market Capitalization (Millions $) 3,023
 Shares Outstanding (Millions) 107
 Employees 211
 Revenues (TTM) (Millions $) 182
 Net Income (TTM) (Millions $) -303
 Cash Flow (TTM) (Millions $) -144
 Capital Exp. (TTM) (Millions $) 206

Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc is a biopharmaceutical company based in Pasadena, California, that is focused on the development of RNA interference (RNAi) therapeutics. The company is dedicated to developing innovative therapies that target diseases with high unmet medical needs, including rare and chronic diseases such as liver diseases, cardiovascular diseases, oncology, and more.

Arrowhead's RNAi technology is based on a gene-silencing technology that uses small RNA molecules that interfere with the expression of specific genes, leading to the inhibition of the disease process. The company's leading RNAi technology platform, called TRiM (Targeted RNAi Molecule), is designed to deliver RNAi therapeutics to specific tissues and organs with high specificity, efficacy, and safety. Arrowhead's TRiM platform is specifically designed to overcome the challenges of effective delivery of RNAi drugs, including stability, targeting, and biodistribution.

The company's lead clinical development program is aimed at the treatment of liver diseases such as alpha-1 antitrypsin deficiency (AATD), hypercholesterolemia, and others. The company has also initiated clinical testing of RNAi therapeutics for cardiovascular diseases, including hypertension and pulmonary arterial hypertension (PAH), and oncology, including liver cancer (hepatocellular carcinoma) and solid tumors.

Arrowhead has collaborations with various pharmaceutical companies and academic institutions, including Takeda Pharmaceutical Company, Amgen, and The University of Texas MD Anderson Cancer Center, among others. The company's management team consists of experienced scientists, entrepreneurs, and executives, including President and CEO Christopher Anzalone, Ph.D.; Chief Medical Officer Javier San Martin, M.D.; and Chief Scientific Officer Kevin Fitzgerald, Ph.D.

Arrowhead Pharmaceuticals Inc is publicly traded on the NASDAQ market under the ticker symbol ARWR. The company has a market capitalization of over $5 billion as of August 2021, reflecting strong investor confidence in its innovative RNAi technology platform and pipeline of promising drug candidates.


   Company Address: 177 E. Colorado Blvd Pasadena 91105 CA
   Company Phone Number: 304-3400   Stock Exchange / Ticker: NASDAQ ARWR
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Promising Developments in RNA Interference Therapeutics for Muscular Dystrophy Treatment

Published Fri, Mar 8 2024 12:30 PM UTC

Arrowhead Pharmaceuticals, a biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, has made significant progress in its efforts to develop effective treatments for various types of muscular dystrophy. In particular, Arrowhead has initiated a Phase 1/2a study of ARO-DM1 for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrop...

Arrowhead Pharmaceuticals Inc

Major Pharmaceutical Preparations Company's Deficit Widens in Fiscal First Quarter of 2024

Arrowhead Pharmaceuticals Inc, a California-based biopharmaceutical company, recently disclosed its fiscal 2024 first-quarter financial results, which were disappointing. The company reported a significant decrease in revenue, falling by -94.323% to $3.55 million compared to the previous reporting season. Additionally, the shortfall per share extended to -$1.24, indicating a decline from the corresponding period a year ago.
However, despite these challenges, it is important to note that the Major Pharmaceutical Preparations industry as a whole experienced a 0.52% rise in revenue during the first quarter of 2024, relative to the same period a year ago. This demonstrates that the struggles faced by Arrowhead Pharmaceuticals are not indicative of the entire industry's performance.

Stock Transactions

Arrowhead Pharmaceuticals Raises $450 Million in Underwritten Offering

Published Fri, Jan 5 2024 10:00 PM UTC


Arrowhead Pharmaceuticals, a California-based biopharmaceutical company, has successfully closed an underwritten registered offering, raising gross proceeds of $450.0 million. The offering involved the sale of 15,790,000 shares of the company's common stock at a price of $28.50 per share. This press release follows an earlier announcement by Arrowhead Pharmaceuticals ab...

Stock Issue News

Arrowhead Pharmaceuticals Secure $450.0 Million in Successful Offering, Boosting Confidence in RNAi Therapeutics

Published Wed, Jan 3 2024 12:00 PM UTC



Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), a leading biopharmaceutical company specializing in RNA interference (RNAi) therapeutics, recently disclosed the successful pricing of an underwritten registered offering of its common stock. This press release summarizes the key details of the announcement, provides context, and analyzes the potential implications fo...

Stock Transactions

Arrowhead Pharmaceuticals' Inducement Grants to Attract Top Talent and Fuel Shareholder Value

Published Fri, Dec 29 2023 9:01 PM UTC

Arrowhead Pharmaceuticals Announces Inducement Grants to New Employees under NASDAQ Listing Rule 5635(c)(4)
Facts:
Arrowhead Pharmaceuticals Inc. recently revealed its decision to offer inducement grants to 32 new employees as part of their employment agreement. This move was approved by the company's Board of Directors on December 28, 2023, under Rule 5635(c)(4) o...






 

Arrowhead Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com